ArticleAmerican journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists2026
Use of failure mode and effects analysis for risk analysis of investigational drug products management in clinical trials.
Article in American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe purpose of this study is to prospectively analyze the entire process of managing investigational drug products (IP) in the investigational drug service (IDS) pharmacy, explore the safety risks and corrective actions in the management of IP, and ensure the safety of participants and the quality of clinical trials.
methodsFailure mode and effects analysis (FMEA) was conducted at a tertiary general hospital. By analyzing the risk priority number (RPN) of each failure mode, failure modes with significant impacts on participant safety, data integrity, and regulatory compliance in clinical trials were identified, and implementation priorities were determined. Corresponding corrective actions were then formulated.
resultsA total of 44 failure modes were identified, with 31 classified as high-risk. The causes of these failure modes were primarily related to factors such as IDS pharmacists failing to strictly review documents, noncompliance with standard operating procedures, and investigators' lack of familiarity with clinical trial protocols. Finally, 5 general and 10 specific corrective actions for particular steps were proposed. Among the top 10 RPN scores, 60.0% were related to the drug dispensing process, and 62.5% of the highest severity scores (5 points) were also associated with this step. The most critical general actions formulated by the team included creating detailed flowcharts for each operational step, developing pocket guides, and enhancing training for pharmacists and investigators.
conclusionThrough the active participation of IDS pharmacy staff, FMEA successfully identified and prioritized potential failure modes in the IDS pharmacy management process. Corrective actions were proposed to ensure participant safety and continuously improve the quality of clinical trials and IP management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.